{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Administration+of+AZD6738", "query": { "intervention": "Administration of AZD6738" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 13, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Administration+of+AZD6738&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-15T00:58:11.427Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03682289", "title": "Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Clear Cell Renal Cell Carcinoma", "Locally Advanced Pancreatic Cancer", "Locally Advanced Malignant Solid Neoplasm", "Metastatic Malignant Solid Neoplasm", "Metastatic Renal Cell Carcinoma", "Metastatic Urothelial Carcinoma", "Metastatic Pancreatic Cancer", "Stage III Pancreatic Cancer", "Stage III Renal Cell Cancer", "Stage IV Pancreatic Cancer", "Stage IV Renal Cell Cancer", "Endometrial Cancer", "Metastatic Castration-resistant Prostate Cancer" ], "interventions": [ { "name": "Ceralasertib", "type": "DRUG" }, { "name": "Olaparib", "type": "DRUG" }, { "name": "Durvalumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Rahul Aggarwal", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 83, "start_date": "2019-01-17", "completion_date": "2028-03-31", "has_results": false, "last_update_posted_date": "2026-04-23", "last_synced_at": "2026-09-15T00:58:11.427Z", "location_count": 3, "location_summary": "Duarte, California • San Francisco, California • Chicago, Illinois", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT03682289" }, { "nct_id": "NCT03527147", "title": "Platform Study for the Treatment of Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma (PRISM Study)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "NHL", "DLBCL", "Non-hodgkin's Lymphoma", "Diffuse Large B Cell Lymphoma" ], "interventions": [ { "name": "AZD9150", "type": "DRUG" }, { "name": "Acalabrutinib", "type": "DRUG" }, { "name": "AZD6738", "type": "DRUG" }, { "name": "Hu5F9-G4", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "AZD5153", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Acerta Pharma BV", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 30, "start_date": "2018-06-19", "completion_date": "2021-03-31", "has_results": false, "last_update_posted_date": "2022-08-15", "last_synced_at": "2026-09-15T00:58:11.427Z", "location_count": 10, "location_summary": "Los Angeles, California • Sarasota, Florida • Atlanta, Georgia + 7 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "New Orleans", "state": "Louisiana" }, { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03527147" }, { "nct_id": "NCT01955668", "title": "AZD6738 First Time in Patient Multiple Ascending Dose Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "11q-deleted Relapsed/Refractory Chronic Lymphocytic Leukaemia (CLL),", "Prolymphocytic Leukaemia (PLL)", "B Cell Lymphomas" ], "interventions": [ { "name": "Administration of AZD6738", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2013-11", "completion_date": "2013-12", "has_results": false, "last_update_posted_date": "2014-06-19", "last_synced_at": "2026-09-15T00:58:11.427Z", "location_count": 1, "location_summary": "La Jolla, California", "locations": [ { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01955668" }, { "nct_id": "NCT04417062", "title": "Olaparib With Ceralasertib in Recurrent Osteosarcoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Osteosarcoma", "Osteosarcoma Recurrent" ], "interventions": [ { "name": "Olaparib", "type": "DRUG" }, { "name": "Ceralasertib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "40 Years", "sex": "ALL", "summary": "12 Years to 40 Years" }, "enrollment_count": 49, "start_date": "2020-11-24", "completion_date": "2026-12-01", "has_results": true, "last_update_posted_date": "2026-08-20", "last_synced_at": "2026-09-15T00:58:11.427Z", "location_count": 4, "location_summary": "San Francisco, California • Boston, Massachusetts • New York, New York + 1 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04417062" }, { "nct_id": "NCT03022409", "title": "A Study to Investigate Biomarker Effects of Pre-Surgical Treatment With DNA Damage Repair (DDR) Agents in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC).", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Head and Neck Squamous Cell Carcinoma" ], "interventions": [ { "name": "Ceralasertib", "type": "DRUG" }, { "name": "Olaparib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 21, "start_date": "2017-09-18", "completion_date": "2021-01-20", "has_results": false, "last_update_posted_date": "2021-08-10", "last_synced_at": "2026-09-15T00:58:11.427Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03022409" }, { "nct_id": "NCT04699838", "title": "Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Naïve Patients With Extensive Stage Small Cell Lung Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Extensive Stage Small Cell Lung Cancer" ], "interventions": [ { "name": "Cisplatin", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Durvalumab", "type": "DRUG" }, { "name": "Ceralasertib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Muhammad Furqan", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2021-04-20", "completion_date": "2027-04", "has_results": false, "last_update_posted_date": "2026-09-03", "last_synced_at": "2026-09-15T00:58:11.427Z", "location_count": 5, "location_summary": "Chicago, Illinois • Indianapolis, Indiana • Iowa City, Iowa + 2 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT04699838" }, { "nct_id": "NCT03801369", "title": "AMTEC IIT: Phase 2 Multiarm Study in TNBC", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Anatomic Stage IV Breast Cancer AJCC v8", "Metastatic Triple-Negative Breast Carcinoma" ], "interventions": [ { "name": "Biopsy", "type": "PROCEDURE" }, { "name": "Capivasertib", "type": "DRUG" }, { "name": "Ceralasertib", "type": "DRUG" }, { "name": "Durvalumab", "type": "BIOLOGICAL" }, { "name": "Olaparib", "type": "DRUG" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Selumetinib", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "Gordon Mills, MD, PhD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2018-12-12", "completion_date": "2024-12-23", "has_results": true, "last_update_posted_date": "2026-02-25", "last_synced_at": "2026-09-15T00:58:11.427Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT03801369" }, { "nct_id": "NCT04090567", "title": "Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Breast Carcinoma", "Anatomic Stage III Breast Cancer AJCC v8", "Anatomic Stage IIIA Breast Cancer AJCC v8", "Anatomic Stage IIIB Breast Cancer AJCC v8", "Anatomic Stage IIIC Breast Cancer AJCC v8", "Anatomic Stage IV Breast Cancer AJCC v8", "Germline BRCA1 Gene Mutation", "Germline BRCA2 Gene Mutation", "HER2/Neu Negative", "Metastatic Breast Carcinoma", "Prognostic Stage III Breast Cancer AJCC v8", "Prognostic Stage IIIA Breast Cancer AJCC v8", "Prognostic Stage IIIB Breast Cancer AJCC v8", "Prognostic Stage IIIC Breast Cancer AJCC v8", "Prognostic Stage IV Breast Cancer AJCC v8" ], "interventions": [ { "name": "Cediranib", "type": "DRUG" }, { "name": "Ceralasertib", "type": "DRUG" }, { "name": "Olaparib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 60, "start_date": "2020-07-28", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-09-14", "last_synced_at": "2026-09-15T00:58:11.427Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04090567" }, { "nct_id": "NCT04704661", "title": "Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Breast Carcinoma", "Advanced Colon Carcinoma", "Advanced Colorectal Carcinoma", "Advanced Endometrial Carcinoma", "Advanced Gastric Carcinoma", "Advanced Gastroesophageal Junction Adenocarcinoma", "Advanced Malignant Solid Neoplasm", "Advanced Salivary Gland Carcinoma", "Anatomic Stage III Breast Cancer AJCC v8", "Anatomic Stage IV Breast Cancer AJCC v8", "Clinical Stage III Gastric Cancer AJCC v8", "Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8", "Clinical Stage IV Gastric Cancer AJCC v8", "Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8", "HER2-Positive Breast Carcinoma", "Malignant Hepatobiliary Neoplasm", "Metastatic Breast Carcinoma", "Metastatic Colon Carcinoma", "Metastatic Colorectal Carcinoma", "Metastatic Endometrial Carcinoma", "Metastatic Gastric Carcinoma", "Metastatic Gastroesophageal Junction Adenocarcinoma", "Metastatic Malignant Solid Neoplasm", "Metastatic Salivary Gland Carcinoma", "Stage III Colon Cancer AJCC v8", "Stage III Colorectal Cancer AJCC v8", "Stage III Major Salivary Gland Cancer AJCC v8", "Stage III Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8", "Stage IV Colon Cancer AJCC v8", "Stage IV Colorectal Cancer AJCC v8", "Stage IV Major Salivary Gland Cancer AJCC v8", "Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8", "Unresectable Breast Carcinoma", "Unresectable Colon Carcinoma", "Unresectable Colorectal Carcinoma", "Unresectable Endometrial Carcinoma", "Unresectable Gastric Carcinoma", "Unresectable Gastroesophageal Junction Adenocarcinoma", "Unresectable Malignant Solid Neoplasm", "Unresectable Salivary Gland Carcinoma" ], "interventions": [ { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Ceralasertib", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Multigated Acquisition Scan", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Trastuzumab Deruxtecan", "type": "BIOLOGICAL" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 51, "start_date": "2021-08-09", "completion_date": "2027-03-31", "has_results": false, "last_update_posted_date": "2026-09-04", "last_synced_at": "2026-09-15T00:58:11.427Z", "location_count": 23, "location_summary": "Irvine, California • Los Angeles, California • Orange, California + 16 more", "locations": [ { "city": "Irvine", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04704661" }, { "nct_id": "NCT03878095", "title": "Testing Olaparib and AZD6738 in IDH1 and IDH2 Mutant Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Malignant Solid Neoplasm", "Refractory Cholangiocarcinoma", "Refractory Malignant Solid Neoplasm" ], "interventions": [ { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Marrow Aspiration", "type": "PROCEDURE" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Ceralasertib", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Olaparib", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2020-01-30", "completion_date": "2027-07-10", "has_results": true, "last_update_posted_date": "2026-08-03", "last_synced_at": "2026-09-15T00:58:11.427Z", "location_count": 13, "location_summary": "Birmingham, Alabama • New Haven, Connecticut • Trumbull, Connecticut + 9 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Trumbull", "state": "Connecticut" }, { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03878095" } ] }